The goal of the ICARA study is to determine if an investigational drug, called bapineuzumab, can help slow the progression of Alzheimer's disease.

Current therapies for Alzheimer's treat the symptoms associated with it, not the disease itself.

It is important for patients and families affected by Alzheimer's to consider participating in clinical studies.

A medical team, including a physician, will monitor participants throughout the study.

There is no charge to participate in this study.